# 17-Hydroxylase Deficiency

Suspect 17-hydroxylase/17,20-lyase deficiency in a patient with hypertension, hypokalemia, absent or incomplete puberty, and deficient sex-steroid production; confirm the CYP17A1-related steroidogenic disorder with targeted biochemical and genetic evaluation.

**Clinical question:** How should clinicians recognize and confirm CYP17A1-related 17-hydroxylase/17,20-lyase deficiency?

Updated: 2026-08-24T18:26:55.500102+00:00

## What matters in practice
- CYP17A1 deficiency is a rare congenital adrenal hyperplasia phenotype in which impaired 17α-hydroxylase and/or 17,20-lyase activity disrupts adrenal and gonadal steroidogenesis. [6][11][18]
- The diagnostic pattern that should prompt targeted evaluation is hypertension with hypokalemia or other electrolyte disturbance plus delayed puberty, sexual infantilism, or primary amenorrhea. [16]
- Assess cortisol, DHEA-S, LH, FSH, karyotype when indicated, and confirm suspected disease with CYP17A1 molecular testing. [16][23]
- Complete combined deficiency impairs cortisol and sex-steroid production; 46,XY individuals may have a female phenotype, whereas 46,XX individuals have chronic anovulation. [5][14][17]

## Recognize the high-yield presentation

Prioritize this diagnosis when reproductive failure and mineralocorticoid-pattern hypertension coexist.

Evaluate for 17-hydroxylase/17,20-lyase deficiency in adolescents or adults with delayed puberty or primary amenorrhea accompanied by hypertension, hypokalemia, or other electrolyte imbalance. A reported 46,XX presentation included low cortisol and DHEA-S with elevated LH and FSH; reported 46,XY presentations include hypertension, hypokalemia, sexual infantilism, delayed bone age, and a female social phenotype. [16]

The disorder is a rare form of congenital adrenal hyperplasia caused by CYP17A1 variants. CYP17A1 encodes enzymatic activities needed for 17α-hydroxylation and 17,20-lyase conversion in steroidogenesis; impairment can affect one or both activities. [6][11][18][23]
- In a phenotypic female with absent pubertal development, obtain gonadotropins and sex-steroid/adrenal steroid testing before attributing the presentation solely to gonadal dysgenesis. Elevated LH and FSH with low DHEA-S and cortisol should broaden evaluation to steroidogenic disease. [16]
- In a patient with apparent resistant or early-onset hypertension plus hypokalemia, actively ask about pubertal development, menstrual history, infertility, and prior karyotype testing. [8][16]

*Clinical features that should redirect evaluation toward CYP17A1-related disease. [5][16][17]*

| Clinical branch | Discriminator | Next diagnostic action |
| --- | --- | --- |
| Phenotypic female with primary amenorrhea or delayed puberty | Hypertension and electrolyte disturbance increase suspicion for 17-hydroxylase deficiency. [16] | Measure cortisol, DHEA-S, LH, and FSH; obtain karyotype when a disorder of sex development is possible. [16] |
| 46,XY disorder-of-sex-development presentation | Combined deficiency may produce a female phenotype because cortisol and sex-steroid production are impaired. [5][14][17] | Use karyotype and targeted CYP17A1 molecular testing to establish etiology. [16][23] |
| Hypertension with hypokalemia and sexual infantilism | This combination has been reported in delayed diagnoses of 17-hydroxylase deficiency. [16] | Perform targeted steroidogenic evaluation and confirm with CYP17A1 analysis. [16][23] |

## Use steroid and gonadotropin patterns to localize the defect

The clinical objective is to distinguish impaired cortisol/sex-steroid synthesis from other causes of amenorrhea or monogenic hypertension.

CYP17A1 performs two linked functions: 17α-hydroxylase converts pregnenolone and progesterone to their 17α-hydroxylated derivatives, and 17,20-lyase supports formation of DHEA and androstenedione. DHEA and androstenedione are androgen precursors; therefore, low DHEA-S in the appropriate phenotype supports impaired androgen-pathway flux. [1][5][23]

Cortisol synthesis requires 17α-hydroxylase activity, whereas sex-steroid synthesis requires both 17α-hydroxylase and 17,20-lyase activity. Thus, combined loss is expected to produce both cortisol deficiency and marked sex-steroid deficiency, while selective residual activity can produce a less complete reproductive phenotype. [14][17]

Use LH and FSH to identify the hypergonadotropic pattern documented in a 46,XX patient with CYP17A1-associated disease. In that setting, a 46,XX karyotype excludes Turner syndrome but does not exclude a steroidogenic cause of pubertal failure; CYP17A1 sequencing established the diagnosis in the reported case. [16]

### Differentiate combined from predominantly 17,20-lyase impairment

CYP17A1-related disease spans combined 17α-hydroxylase/17,20-lyase deficiency and isolated 17,20-lyase deficiency. Mutations in CYP17A1 can impair one or both catalytic functions; isolated 17,20-lyase deficiency has also been associated with defects in redox partner proteins, including POR and cytochrome b5. [11][17]
- Low cortisol together with low DHEA-S supports combined impairment in the correct clinical setting. [16]
- If sex-steroid deficiency predominates with preserved cortisol response, consider a predominantly lyase phenotype and broaden molecular assessment beyond CYP17A1 when clinically appropriate. [16][17]

*Biochemical interpretation in suspected 17-hydroxylase/17,20-lyase deficiency. [1][14][16][17]*

| Finding | Physiologic implication | Clinical use |
| --- | --- | --- |
| Low cortisol | Supports impaired 17α-hydroxylase-dependent cortisol synthesis. [14][16] | Evaluate with other steroidogenic and clinical findings rather than as an isolated cause of adrenal insufficiency. |
| Low DHEA-S | Supports reduced androgen-pathway precursor production. [1][16] | Interpret alongside pubertal development, sex-steroid status, and gonadotropins. |
| Elevated LH and FSH | Supports hypergonadotropic reproductive-axis dysfunction in the reported CYP17A1 phenotype. [16] | In primary amenorrhea, pair with karyotype and steroidogenic testing. |
| Female phenotype in 46,XY individual | Consistent with severely impaired sex-steroid production in complete combined deficiency. [5][17] | Obtain karyotype and molecular confirmation; coordinate disorder-of-sex-development care. |

## Confirm molecularly and define the reproductive phenotype

A molecular diagnosis clarifies enzyme category, informs family counseling, and avoids prolonged misclassification.

Confirm suspected 17-hydroxylase/17,20-lyase deficiency with molecular testing of CYP17A1. Direct sequencing of CYP17A1 coding regions has been used for molecular diagnosis of congenital adrenal hyperplasia, and case-based diagnosis has been established by identifying pathogenic CYP17A1 variation after biochemical and karyotype evaluation. [16][23]

Use karyotype selectively but early when the phenotype includes absent puberty, primary amenorrhea, or disorder-of-sex-development features. Both 46,XX and 46,XY phenotypes occur: complete combined deficiency can result in a prepubertal female phenotype without treatment, while 46,XX patients may have chronic anovulation and can develop large cystic ovaries that may hemorrhage. [16][17]

Do not infer phenotypic severity solely from the diagnostic label. Partial enzymatic defects may permit some secondary sexual characteristics or cyclic menses in 46,XX individuals, whereas complete deficiency produces more profound interruption of cortisol and sex-steroid synthesis. [17]
- Document blood pressure, potassium, pubertal history, menstrual history, genital phenotype, and bone-age history at the diagnostic visit; hypertension, hypokalemia, sexual infantilism, and delayed bone age have occurred together in reported 46,XY disease. [16]
- When a CYP17A1 variant is identified, integrate genotype with steroid profile rather than assuming uniform residual enzymatic activity. CYP17A1 variants may impair one or both enzymatic functions. [11][17]

*Phenotype-directed testing in suspected CYP17A1 deficiency. [16][17][23]*

| Presentation | Tests that change the next step | Interpretation prompting confirmation |
| --- | --- | --- |
| Primary amenorrhea with delayed puberty | Cortisol, DHEA-S, LH, FSH, karyotype. [16] | Low cortisol and DHEA-S with elevated LH/FSH support steroidogenic evaluation; proceed to CYP17A1 testing. [16][23] |
| Hypertension with hypokalemia and absent/incomplete puberty | Focused reproductive history, electrolytes, cortisol, DHEA-S, karyotype when indicated. [16] | The combined endocrine and mineralocorticoid-pattern presentation warrants CYP17A1-directed molecular testing. [16][23] |
| 46,XY female phenotype | Karyotype, adrenal and sex-steroid evaluation, CYP17A1 testing. [5][16] | Complete combined deficiency is compatible with a female phenotype in 46,XY individuals. [5][17] |

## Treat immediate endocrine and reproductive consequences through multidisciplinary care

Management must address blood pressure and electrolyte abnormalities while planning long-term endocrine and reproductive care.

At presentation with severe hypertension or hypokalemia, prioritize blood-pressure assessment and electrolyte correction while endocrine testing proceeds; these abnormalities are characteristic reported manifestations and may be present despite a delayed diagnosis. [16]

Refer confirmed or strongly suspected cases to an endocrinologist experienced in congenital adrenal hyperplasia and, when applicable, a multidisciplinary disorders-of-sex-development team. The care plan should incorporate cortisol deficiency, sex-steroid deficiency, karyotype-associated reproductive anatomy, and the patient's goals for pubertal induction, hormone replacement, fertility, and gonadal management. The need for sex-hormone replacement in congenital adrenal hyperplasia with 17α-hydroxylase/17,20-lyase deficiency is recognized in pediatric review literature. [19]

For 46,XX patients, evaluate pelvic anatomy and ovarian status when symptoms, examination, or imaging concern exists, because chronic anovulation in complete disease has been associated with large cystic ovaries that can hemorrhage. [17] Fertility counseling should be individualized; in vitro fertilization has been reported in this condition. [17]
- Escalate urgently for symptomatic hypokalemia, severe hypertension, or concern for adrenal insufficiency; obtain endocrine input before initiating therapies that could substantially alter diagnostic steroid profiles when the patient is clinically stable. [16]
- Provide genetic counseling after molecular confirmation because the condition is caused by CYP17A1 mutations and phenotype can vary with the degree of functional impairment. [11][18]

*Management priorities after suspected or confirmed diagnosis. [16][17][19]*

| Clinical priority | Action | Reason |
| --- | --- | --- |
| Hypertension or hypokalemia | Assess severity and correct clinically significant abnormalities while completing endocrine evaluation. [16] | Both are reported manifestations and may create immediate cardiovascular or arrhythmic risk. |
| Cortisol and sex-steroid deficiency phenotype | Coordinate endocrinology-directed replacement planning and longitudinal biochemical assessment. [14][19] | Combined enzyme impairment disrupts cortisol and sex-steroid synthesis. [14] |
| 46,XX chronic anovulation | Assess for ovarian cystic complications when clinically indicated. [17] | Large cystic ovaries may develop and can hemorrhage. [17] |
| 46,XY or complex sex-development phenotype | Use multidisciplinary, patient-centered counseling before irreversible reproductive or gonadal decisions. [5][16][17] | Phenotype, karyotype, and reproductive goals vary substantially across affected individuals. |

## References
1. AKEEGA — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=8245a990-3268-4613-b5c5-9537858a1eb9
2. DailyMed - AKEEGA- niraparib tosylate monohydrate and abiraterone acetate tablet, film coated — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8245a990-3268-4613-b5c5-9537858a1eb9&audience=consumer
3. 21- hydroxylase- deficiency primary adrenal insufficiency in ... — jmg.bmj.com — https://jmg.bmj.com/content/early/2023/09/15/jmg-2022-108952.full.pdf
4. Perspectives of Rare Disease Experts on Newborn ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804586
5. Female phenotype with male karyotype: a clinical enigma — casereports.bmj.com — https://casereports.bmj.com/content/2017/bcr-2016-219082
6. Congenital adrenal hyperplasia — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31431-9/abstract
7. Immune checkpoint blockade as an accelerator of adrenal ... — jitc.bmj.com — https://jitc.bmj.com/content/jitc/14/4/e014454.full.pdf
8. Genetic screening for monogenic hypertension in ... — jmg.bmj.com — https://jmg.bmj.com/content/57/8/571
9. Management of adolescents with congenital adrenal ... — www.thelancet.com — https://www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70138-4/abstract
10. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal ... — www.nature.com — https://www.nature.com/articles/srep35354
11. Molecular Genetics of Steroidogenic Enzyme Deficiencies — www.nature.com — https://www.nature.com/nature-index/topics/l4/molecular-genetics-of-steroidogenic-enzyme-deficiencies
12. Recapitulation of two genomewide association studies on ... — www.nature.com — https://www.nature.com/articles/jhg201031
13. CYP17A1 deficient XY mice display susceptibility to ... — www.nature.com — https://www.nature.com/articles/s41598-020-65601-0
14. Expression of Bovine 17α-Hydroxylase Cytochrome P-450 ... — www.science.org — https://www.science.org/doi/10.1126/science.3535074
15. Fertility and pregnancy in adrenal insufficiency — www.sciencedirect.com — https://www.sciencedirect.com/org/science/article/pii/S2049361424000169
16. Severe hypertension caused by 17α-hydroxylase deficiency: A case report — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2405844023012690
17. Lipoid Congenital Adrenal Hyperplasia - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/lipoid-congenital-adrenal-hyperplasia
18. Novel compound heterozygous CYP17A1 mutations ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0039128X25000030
19. Congenital Adrenal Hyperplasia | Pediatrics In Review — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/21/5/159/61564/Congenital-Adrenal-Hyperplasia
20. Neonatal Differences in Sexual Differentiation — publications.aap.org — https://publications.aap.org/pediatriccare/article/doi/10.1542/aap.ppcqr.396522/206145/Neonatal-Differences-in-Sexual-Differentiation
21. Further Studies on the Treatment of Congenital Adrenal ... — publications.aap.org — https://publications.aap.org/pediatrics/article/102/Supplement_1/215/28118/Further-Studies-on-the-Treatment-of-Congenital
22. Environmental Heat Illness in Children Teen Pregnancy A ... — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/1741664
23. Molecular Diagnosis of Congenital Adrenal Hyperplasia in ... — applications.emro.who.int — https://applications.emro.who.int/imemrf/Iran_J_Pediatr/Iran_J_Pediatr_2011_21_2_139_150.pdf
24. Web Annex C. Evidence to decision tables for diagnosis ... - IRIS — iris.who.int — https://iris.who.int/bitstreams/7497763a-f61a-4f6a-b314-1ff40fbda398/download

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.